Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


amy.gillespie@psych.ox.ac.uk


+44 (0)1865 618324


OSF


ORCID ID https://orcid.org/0000-0003-4640-699X

Amy Gillespie

BSc, MSc, PhD

Postdoc

  • Senior Post-doctoral Researcher
  • Project Manager for Oxford Health BRC Depression Therapeutics Theme

I am working as a postdoctoral researcher with the Psychopharmacology and Emotion Research Lab (PERL), led by Professor Catherine Harmer. I am broadly interested in research which helps us understand the mechanisms of psychiatric problems and their treatments. 

My main project investigates the effect of a 5-HT4 partial agonist on emotional and non-emotional cognitive processing in a) unmedicated patients with depression (RESTAND study) and b) patients with depression resistant to SSRI/SNRIs (RESTART study). I also co-ordinate day-to-day running of the COSIE study, a large longitudinal online study investigating risk and resilience factors during the pandemic via online assessments of emotional cognition.  

My PhD was also in psychopharmacology research, focused on a) the differences between participants with treatment-resistant and treatment-responsive schizophrenia and b) the effects of clozapine on DNA methylation (an epigenetic process) in treatment-resistant schizophrenia at King's College London. 

I enjoy working on improving and standardising cognitive tasks and reproducible analysis pipelines, supporting colleagues and collaborators in setting up their studies, supervising masters students, co-chairing the Patients Active in Research Strategy group, public engagement events and occasional bursts of tweeting.